← Search & browse all drugs
CARDIOVASCULAR SYSTEM › VASOPROTECTIVES › OTHER VASOPROTECTIVES › Other vasoprotectives
beperminogene perplasmid
C05XX01
Forms & Strengths
- Intra-arterial injection, 0.2 mg
- Available in single-dose vials of 2 mL
Adult Dosing
- Administer 0.2 mg once via intra-arterial injection
- No dose adjustment for renal or hepatic impairment
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Use in patients under 18 years old is not recommended
Indications
- Treatment of critical limb ischemia (CLI) in patients with severe intermittent claudication or ischemic ulcers
- Improvement of wound healing and prevention of amputation in CLI patients
Mechanism of Action
- Gene therapy product encoding the FGF-1 gene
- Stimulates angiogenesis through expression of fibroblast growth factor 1 (FGF-1) in ischemic tissues
Contraindications
- Hypersensitivity to beperminogene perplasmid or excipients
- Tumors of vascular origin or active malignancy
Adverse Reactions
- Most common: injection site reaction, fever
- Serious: potential increased risk of malignancy
Drug Interactions
- Co-administration with anti-angiogenic therapies is not recommended
- Use with caution in patients taking immunosuppressive agents
Curated Content: Needs Vetting Before Put to Clinical Use